FTC to keep eye on pharmacy benefit groups; Takeda to sell Teva's Copaxone in Japan; Sanofi loses patent fight;

@FiercePharma: Boehringer Ingelheim looks for a buyer for its troubled Bedford operation. News | Follow @FiercePharma

@EricPFierce: Will wonders--and AstraZeneca's patent battles over Prilosec--never cease? Apotex ordered to pay $76M. News | Follow @EricPFierce

@CarlyHFierce: Can Celgene, Eli Lilly and GE Ventures help turn NYC into a biotech hub? Story | Follow @CarlyHFierce

> Members of the Federal Trade Commission (FTC) said they know the FTC needs to keep an eye on the pharmacy benefits management industry after mergers in recent years have concentrated that business. Story

> Teva Pharmaceutical Industries ($TEVA) has licensed its top-selling drug, multiple sclerosis treatment Copaxone, to Takeda in Japan. Story

> Australia's top court ruled that Apotex' generic versions of Sanofi's ($SNY) rheumatoid arthritis drugs Arava and Arabloc do not violate Sanofi's patents. Story

> India will show off some of its best drug manufacturing facilities to visiting health ministers from Kenya, Ghana, South Africa, Vietnam, Egypt and the Philippines as it works to convince them that publicity over manufacturing problems at some facilities is not reflective of the whole industry. Story

> Jonathan Emms, Pfizer's ($PFE) managing director in the U.K., becomes president of the Association of the British Pharmaceutical Industry (ABPI) next year. Story

Medical Device News

@FierceMedDev: St. Jude Medical to study neuromodulation combo treatment for back and leg pain. More | Follow @FierceMedDev

@MarkHFierce: Patients' attorneys say J&J either lost or wiped out vital docs about vaginal mesh implants vital to their lawsuits. Story | Follow @MarkHFierce

@MichaelGFierce: Researchers' pitch: An injectable, sustained-release rotator cuff treatment. News | Follow @MichaelGFierce

@GalenMoore: Boston hand-wringing alert: Celgene, Lilly back $100M VC fund for NY biotech startups. Story | Follow @GalenMoore

> FDA cautions some Philips external defibrillators may still be duds. More

> 23andMe hit with lawsuit over 'meaningless' gene tests. Article

Biotech News

@FierceBiotech: Organogenesis preps 'heart breaking' cuts as Medicare slashes reimbursement. More | Follow @FierceBiotech

@JohnCFierce: Hey, you VCs looking at getting into the NY fund, drop me a line with your thoughts. | Follow @JohnCFierce

@DamianFierce: As everyone goes public, Zafgen goes it alone, raises another $45M in Series E cash. Item | Follow @DamianFierce

@EmilyMFierce: ICYMI: Key hep C protein revealed, paving the way for new vaccines. News | Follow @EmilyMFierce

> 5AM Ventures has $250M and an eye out for early-stage biotechs. News

> Medicines Co. buys out Rempex's pipeline for hospital-acquired infections. Story

> Immunotherapy startup lands $120M Series A for cancer-killing drugs. More

Drug Delivery News

> Study: 'Worm-shaped' nanoparticles best at infiltrating breast cancer. More

> BioDelivery Sciences pushes diabetic pain gel to PhIII with FDA nod. News

> Danish nanorobots offer hot, cold delivery. Article

> Researchers' pitch: An injectable, sustained-release rotator cuff treatment. Piece

> Unilife bags Novartis deal for injectable tech. Story

> Bind founders publish data showing nanomed transport ability. Item

Diagnostics News

> LabCorp launch heightens crowding of BRCA predictive cancer test market. Story

> Biodesix grabs an $8.3M Series E for personalized lung cancer treatment test. Report

> Investors panic over BioReference Laboratories' reimbursement woes. Article

> U.K. team speeds brain cancer diagnostic process. News

> BioMérieux, Biocartis shut down molecular Dx development partnership. More

> Myriad Genetics inches closer to acquiring Crescendo Bioscience. Item

And Finally... Flu vaccines have become more targeted with one especially made for the elderly, some that are inhaled and one made from cells injected into insects for those allergic to eggs. Story

 

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.